Volume 12, Number 11—November 2006
Research
Schistosomiasis among Travelers: New Aspects of an Old Disease
Eli Schwartz*†, Galit Artom‡, Esther Marva§, Marc Victor Assous§, Galia Rahav*†, and Eli Schwartz*†
Table 1
Clinical and laboratory data for patients with schistosomiasis, by stage of disease, Israel, 1993–2005
| Acute (n = 42) | Chronic (n = 23) | Asymptomatic (n = 48) | p value | |
|---|---|---|---|---|
| Age ± SD, y | 28.1 ± 8.0 | 25.1 ± 2.6 | 27.2 ± 6.8 | NS* |
| Male:female ratio | 2.63:1 | 4.5:1 | 2.5:1 | NS |
| Exposure, weeks ± SD | 2.3 ± 1.9 | 4 ± 5.8 | 2.1 ± 0.8 | NS |
| Exposure to symptoms, weeks ± SD | 3.1 ± 2.7 | 58.0 ± 31.5 | – | <0.001† |
| Eosinophil count, ×109/L ± SD | 2,374 ± 1,937 | 864 ± 529 | 1,363 ± 1,490 | <0.05† NS‡ |
| Schistosoma haematobium§ | 42.5% | 60.9% | 27.1% | NS |
| S. mansoni§ | 27.5% | 0% | 52.1% | <0.05†‡ |
| Ova detection | 25% | 56.5% | 14.6% | <0.02† NS‡ |
| Serologic diagnosis | 95% | 96% | 89.5% | NS
*NS, not significant. |
*NS, not significant.
†Comparison between acute and chronic schistosomiasis.
‡Comparison between acute and asymptomatic schistosomiasis.
§In 14.7% of all cases, the test used was not species specific.
Page created: October 14, 2011
Page updated: October 14, 2011
Page reviewed: October 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.